Trial
NCT06522373
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
—
Condition
Leukemia
Intervention
MT-0169
Why stopped
PI Request
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-15